To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
A SIMOPRO project supported by SATT Paris-Saclay: in vivo validation of the efficacy of the DTR8 molecule, developed and patented at SIMOPRO (Department of Medicines and Technologies for Health) in collaboration with Inserm, as a treatment for glomerulonephritis rapidly progressive.
Last April, a delegation of experts from the DRF visited colleagues at the Butantan Institute of São Paulo, a biomedical research center that has had close links with several researchers at the Joliot Institute since 2014. This mission is is concluded by the signing of a framework agreement between the two institutes in the field of therapeutic and vaccine innovation.
Two Research Teams from I2BC@Saclay and SPI (LI2D, Marcoule), in collaboration with IRAMIS, highlight the very strong affinity of silica nanoparticles for proteins with RGG motifs (family of binding proteins). RNA), especially when these are methylated. These results are important for the development of safe by design approaches.
The SHFJ LDM-PET team (GIP Cyceron, Caen), in collaboration with the University Hospital of Caen, successfully used, for the first time in the clinic, the radiopharmaceutical drug developed and produced by the researchers of the team. , the [18F] Fludarabine. This drug, which is innovative for lymphoproliferative diseases, has been shown to be more effective in terms of specificity and sensitivity than its current counterpart, [18F] FDG.
Collaborative work between the SBIGeM (I2BC@Saclay) and the Marseille Cancer Research Center, published in Molecular Cell, illuminates the mechanistic basis and genetic control of homologous recombination, a mechanism for repairing DNA breaks responsible for chromosome exchange during meiosis. However, canonical models do not explain the complexity of meiotic recombination profiles and this study, which reconstructs reaction intermediates, constitutes a major advance in the understanding of this mechanism.
In a study published in Analytical Chemistry, the Mass Spectrometry Research Team of the Laboratory Drug Metabolism Research Laboratory (SPI) demonstrated the interest of Orbitrap Fusion, a state-of-the-art mass spectrometer for the identification of relevant metabolites based on their masses and isotopes measured with high accuracy.
As part of a collaboration with MIRCen (Institute of Biology François Jacob) and SBIGeM, SCBM researchers have developed functional micellar nanovectors capable of targeting a population of cancer cells.
The first CEA functional genomics symposium was held on April 4-5. The meeting, led by the CNRGH (National Center for Research in Human Genomics), took place on the CEA site in Fontenay-aux-Roses. Many researchers from the Frédéric Joliot Institute were invited.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.